Literature DB >> 16011612

Recurrent herpes labialis: a pilot study of the efficacy of zinc therapy.

F Femiano1, F Gombos, C Scully.   

Abstract

BACKGROUND: The objective of this study was to investigate the effect of zinc on recurrent herpes labialis. MATERIALS/
METHODS: Twenty patients (12 females; median age 26.6 years) with a history of recurrent herpes labialis >6 episodes each year were treated with systemic zinc sulphate 22.5 mg twice daily for the months of February, March, September and October. All patients were followed for 12 months.
RESULTS: Herpetic lesions reduced to <4 episodes (average 3) for the 12 months and the duration was <7 days for each episode (average 5.7).
CONCLUSIONS: Systemic zinc sulphate appeared to reduce both the number of episodes and the time to recovery of herpes labialis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16011612     DOI: 10.1111/j.1600-0714.2005.00327.x

Source DB:  PubMed          Journal:  J Oral Pathol Med        ISSN: 0904-2512            Impact factor:   4.253


  8 in total

Review 1.  Suppression of herpes simplex virus 1 reactivation in a mouse eye model by cyclooxygenase inhibitor, heat shock protein inhibitor, and adenosine monophosphate.

Authors:  Yoshikazu Shimomura; Shiro Higaki; Keizo Watanabe
Journal:  Jpn J Ophthalmol       Date:  2010-06-25       Impact factor: 2.447

Review 2.  Zinc supplementation as an adjunct therapy for COVID-19: Challenges and opportunities.

Authors:  Vidyasagar Chinni; John El-Khoury; Marlon Perera; Rinaldo Bellomo; Daryl Jones; Damien Bolton; Joseph Ischia; Oneel Patel
Journal:  Br J Clin Pharmacol       Date:  2021-06-02       Impact factor: 3.716

3.  Comparative analysis of salivary zinc level in recurrent herpes labialis.

Authors:  Faezeh Khozeimeh; Nasim Jafari; Ahmad Movahedian Attar; Shahram Jafari; Masoud Ataie
Journal:  Dent Res J (Isfahan)       Date:  2012-01

4.  Randomised controlled trial for high-dose intravenous zinc as adjunctive therapy in SARS-CoV-2 (COVID-19) positive critically ill patients: trial protocol.

Authors:  Marlon Perera; John El Khoury; Vidyasagar Chinni; Damien Bolton; Liang Qu; Paul Johnson; Jason Trubiano; Christine F McDonald; Daryl Jones; Rinaldo Bellomo; Oneel Patel; Joseph Ischia
Journal:  BMJ Open       Date:  2020-12-02       Impact factor: 2.692

5.  Efficacy of Oral Zinc Sulfate Supplementation on Clearance of Cervical Human Papillomavirus (HPV); A Randomized Controlled Clinical Trial.

Authors:  Hale Ayatollahi; Elham Rajabi; Zahra Yekta; Zahra Jalali
Journal:  Asian Pac J Cancer Prev       Date:  2022-04-01

6.  Efficacy of Pleuran (β-Glucan from Pleurotus ostreatus) in the Management of Herpes Simplex Virus Type 1 Infection.

Authors:  Ingrid Urbancikova; Dana Hudackova; Juraj Majtan; Zuzana Rennerova; Peter Banovcin; Milos Jesenak
Journal:  Evid Based Complement Alternat Med       Date:  2020-04-13       Impact factor: 2.629

7.  Comparative study of serum zinc concentration in recurrent herpes labialis patients and healthy individuals.

Authors:  Zahra Ranjbar; Maryam Zahed; Mohammad Ali Ranjbar; Zahra Shirmardan
Journal:  BMC Oral Health       Date:  2020-10-28       Impact factor: 2.757

8.  A pilot double-blind safety and feasibility randomized controlled trial of high-dose intravenous zinc in hospitalized COVID-19 patients.

Authors:  Oneel Patel; Vidyasagar Chinni; John El-Khoury; Marlon Perera; Ary S Neto; Christine McDonald; Emily See; Daryl Jones; Damien Bolton; Rinaldo Bellomo; Jason Trubiano; Joseph Ischia
Journal:  J Med Virol       Date:  2021-03-09       Impact factor: 20.693

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.